Skip to content
OpenDue September 18, 2026·Updated June 17, 2026

DoW Duchenne Muscular Dystrophy Clinical/Translational Award

Dept. of the Army -- USAMRAA

About this opportunity

Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged. Distinctive Features: The FY26 CTRA offers two funding levels: • Funding Level 1 to support smaller, less complex preclinical and/or clinical research. • Funding Level 2 to support larger, more complex preclinical and/or clinical research. The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partner...

Finding similar opportunities...